Education
About Us
Working with TipRanks
Follow Us
Genenta Science SpA Sponsored ADR (GNTA)
:GNTA
RESEARCH TOOLSreports
GNTA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.20 - $7.28
Previous Close$5.5
Volume13.55K
Average Volume (3M)34.11K
Market Cap
$69.50M
Enterprise ValueN/A
Total Cash (Recent Filing)€15.47M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.35
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding18,289,865
10 Day Avg. Volume4,452
30 Day Avg. Volume34,107
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Genenta Science SpA Sponsored ADR News
PremiumCompany Announcements
Genenta Science Enhances Manufacturing Agreement with AGC Biologics
PremiumCompany Announcements
Genenta Science Updates ATM Sales Agreement with New Agent
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsData from the ongoing P1/2 program for GBM has demonstrated 2-year survival rates of 25%, exceeding historical control of ~15%.
Market OpportunitiesTemferon demonstrating potential across multiple indications could open the door to substantial market opportunities, particularly as it addresses areas with significant unmet medical need.
Regulatory ApprovalGenenta receives approval to initiate a Phase 1 clinical trial for Temferon in metastatic renal cell cancer, marking a key milestone as it expands Temferon’s application into a new therapeutic area.
Bears Say
Clinical TrialsThe P1 pilot trial in mRCC is expected to be a very important study in terms of demonstrating Temferon's ability to alter the tumor microenvironment (TME) in the clinic.
Program ExpansionThere are expectations for additional updates in their Glioblastoma program.
---
Ownership Overview
12.60%
Insiders
―
Mutual Funds
1.91% Other Institutional Investors
85.49% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GNTA FAQ
What was Genenta Science SpA Sponsored ADR’s price range in the past 12 months?
Genenta Science SpA Sponsored ADR lowest stock price was $2.20 and its highest was $7.28 in the past 12 months.
What is Genenta Science SpA Sponsored ADR’s market cap?
Genenta Science SpA Sponsored ADR’s market cap is $69.50M.
When is Genenta Science SpA Sponsored ADR’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Genenta Science SpA Sponsored ADR’s earnings last quarter?
Genenta Science SpA Sponsored ADR released its earnings results on Oct 24, 2022. The company reported -$0.136 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.034.
Is Genenta Science SpA Sponsored ADR overvalued?
According to Wall Street analysts Genenta Science SpA Sponsored ADR’s price is currently Overvalued.
Does Genenta Science SpA Sponsored ADR pay dividends?
Genenta Science SpA Sponsored ADR does not currently pay dividends.
What is Genenta Science SpA Sponsored ADR’s EPS estimate?
Genenta Science SpA Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genenta Science SpA Sponsored ADR have?
Genenta Science SpA Sponsored ADR has 18,289,865 shares outstanding.
What happened to Genenta Science SpA Sponsored ADR’s price movement after its last earnings report?
Genenta Science SpA Sponsored ADR reported an EPS of -$0.136 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went down -3.226%.
Which hedge fund is a major shareholder of Genenta Science SpA Sponsored ADR?
Currently, no hedge funds are holding shares in GNTA
---
Genenta Science SpA Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
5.18%
12-Months-Change
Fundamentals
Return on Equity
-54.30%
Trailing 12-Months
Asset Growth
-37.82%
Trailing 12-Months
Company Description
Genenta Science SpA Sponsored ADR
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
---
GNTA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
BioMarin Pharmaceutical
―
Sarepta Therapeutics
―
Bluebird Bio
―
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering GNTA
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
+5.73%
reiterated a buy rating 6 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +5.73% per trade.
---